New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors

We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.

This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.

The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.

Latest In Research


FDA approves new treatment for extensive-stage small cell lung cancer

From Combination Therapy for SCLC On March 18, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of adult patients …


El Paso County Public Health advises people to test homes for radon

From COLORADO SPRINGS, Colo. (KKTV) January was National Radon Action Month Radon and Lung cancer: “Radon is a clear, odorless, colorless radioactive gas that seeps through the soil from the breakdown of uranium,” said Marla Luckey,…


Antibiotics or anti-inflammatory drugs may help combat lung cancer

from MIT News Bacteria promote lung tumor development, study suggests MIT cancer biologists have discovered a new mechanism that lung tumors exploit to promote their own survival: These tumors alter bacterial populations within the lung, pr…


New Treatment Options for ROS1, BRAF, and NTRK Alterations in NSCLC

from OncLive The scope of targeted therapies has extended more in non–small cell lung cancer (NSCLC), especially with the recent FDA approval of larotrectinib (Vitrakvi) for patients with NTRK gene fusions irrespective of the primary tumor…


Molecular profiling could catch lung cancer early and lead to new treatments

From Medical Express Molecular profiling to catch lung cancer early The world's first genetic sequencing of precancerous lung lesions could pave the way for very early detection and new treatments, reports a new study led by University Coll…


New Protein Found Linked to Lung Cancer Treatment Resistance

From MedExpress Lung cancer remains a major cause of mortality across the globe, although we are gaining a deeper understanding of the genetic background behind this disease, including the mutations that promote it. Mutation in the gene EGFR…


What happens when the doctor blames you for your own cancer?

How bias in the medical community hurts lung cancer patients. from The Washington Post Not long ago, I was working in a busy teaching hospital’s intensive-care unit, poring over EKGs, examining X-rays and reviewing medication orders. I re…


Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

from EurekAlert University of Colorado Study Patients now living a median 6.8 years: According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chan…


Lung Cancer Deaths are 28 Percent Lower in California

From UC San Diego Health State’s long-term, aggressive tobacco control programs cited as primary reason Early adoption of tobacco control efforts in California led to fewer people ever smoking, reduced the amount used by those who do smok…


First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial

From Specialty Pharmacy Times Clinical Trial results: First-line immunotherapy combo fails: New study shows that first-line immunotherapy that uses durvalumab (Imfinzi, AstraZeneca) or the combination of durvalumab and tremelimumab failed t…

Read More